MediLexicon Logo
MediLexicon Logo
Abbreviations        Abbrev Definitions        Dictionary        ICD9 Codes        Equipment        Hospitals        Drugs        More..
  

Useful Websites

Medical Tourism
Compare and save on surgery

Global Translations
Medical and Clinical Translation

specialistinfo.com
Details of over 40,000 UK Specialists and over 42,000 GPs

Global RPH
medical software

Doctors Lounge
Ask a Doctor and Disease Information

Health News
from Medical News Today.

MRCP 1 Revision
123 Doc medical courses for junior doctors.

CoreyNahman
pharmaceutical news daily

Hospital Search
Worldwide hospital database, search by country or keyword.

Metric Conversions
The Converter Site - unit conversion tool.
home > drug information > Caverject

Caverject (alprostadil)


Company: Upjohn
Approval Status: Approved on July 6, 1995
Treatment for: impotence
Areas: Nephrology/Urology

| General Information | Side Effects | Literature References | Additional Information |


General Information

Other Useful Resources

Caverject is the first prescription drug approved for impotence.

It is self-injected into the penis shortly before sexual intercourse. The drug creates an erection by relaxing the smooth muscle tissue and dilating the major artery in the penis, which enhances the blood flow to the penis.



< back to top

Side Effects

The drug's most common side effect is penile pain. Other side effects include bleeding at the injection site and an unhealthy, prolonged erection of four to six hours.



< back to top

Literature References

Chen, J, Godschalk, M, et al. The Lowest Effective Dose of Prostaglandin E1 as Treatment for Erectile Dysfunction. The Journal of Urology 1995; 153: 80-81. Chen, J, Godschalk, M, et al. Prostaglandin E1 as Treatment for Erectile Failure in Elderly Men, Journal of American Geriatrics Society 1994; 42:1263-1265.



< back to top

Additional Information

For the estimated 10 to 20 million American men who suffer from impotence, Caverject provides an alternative to devices previously approved by FDA. A vacuum device involves placing a cylinder-like device and attached pump over the penis. By using the pump, blood is drawn into the penis, creating an erection. A constriction band is then placed at the base of the penis to maintain erection. A second treatment option, the penile implant, involves the surgical placement of cylinders in the penis and is available in a variety of designs.

FDA approved Caverject to treat impotence caused by neurological, vascular or psychological dysfunction. While psychological factors such as anxiety and depression can lead to sexual dysfunction, more than 85% of impotence cases have a physical cause, according to the Impotence Institute of America. A complete physical examination is important so that any underlying condition can be diagnosed and treated. Some common causes of impotence are diabetes, arteriosclerosis (hardening of the arteries), and high blood pressure. Also impotence has reportedly been caused by 16 of the 200 most commonly prescribed drugs, including drugs for high blood pressure, heart disease, and depression.



< back to top



The FDA drug information shown here is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

new forum





pda medical dictionary
pda software - $15

PDA Medical Dictionary

only $15

Take MediLexicon's abbreviations search with you where-ever you go with our PDA software. As an extra, this software is available with an extra medical dictionary...

>> Click here for more on the PDA Medical Dictionary <<




add to google

Add our searches to your Google homepage.

Add to Google

The 60 seconds challenge: Add these searches to your Google homepage within 60 seconds - simply click here and follow these instructions


Receive the latest medical news on your Google homepage.

Add to Google

The 60 seconds challenge: Receive the latest medical news on your Google homepage within 60 seconds - simply click here and follow these instructions





Privacy Policy   |    Disclaimer      

MediLexicon International Ltd, UK Office: +44 (0) 1625 415 347
MediLexicon International Ltd © 2009 All rights reserved.